United States · Series C startup

Who invested in Xcel Pharmaceuticals

2 rounds we have observed, with the one investor named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Funding summaryUpdated 27 Oct 2026

$88Mraised across 2 rounds since 2003, from 2 sources

$62MDebt$26MSeries C
Latest round
Debt, $62MApr 2003
Investors
1
See who backed them

The funding story

Each circle is a round, placed by date and sized by amount. The line above is the running total.

2004
$62MDebt$26MSeries C
First round
Debt, $62M
Apr 2003
Biggest round
$62M
Debt · Apr 2003

The rounds

  1. Apr 2003
    Debt$62M

    No investor was named in the report.

    From a historical funding record

  2. Apr 2003
    Series C$26M1 new

    From a historical funding record

The exit

ExitBuyerPriceWhen
AcquiredValeant Pharmaceuticals InternationalundisclosedFeb 2005

From historical deal records. Wrong? Tell us.

Everyone who backed them

Ferrer Freeman & CompanyPrivate equity1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about Xcel Pharmaceuticals

Who invested in Xcel Pharmaceuticals?

Xcel Pharmaceuticals's investors include Ferrer Freeman & Company.

How much has Xcel Pharmaceuticals raised?

Xcel Pharmaceuticals has raised $88M across 2 rounds since 2003.

When did Xcel Pharmaceuticals last raise?

Xcel Pharmaceuticals's most recent round was a Series C of $26M in Apr 2003.

What was Xcel Pharmaceuticals's biggest round?

Xcel Pharmaceuticals's largest round on record is $62M (Debt), in Apr 2003.

Who backed Xcel Pharmaceuticals first?

Xcel Pharmaceuticals's first round on record, in Apr 2003, was backed by Ferrer Freeman & Company.

What stage is Xcel Pharmaceuticals at?

Xcel Pharmaceuticals's latest named round is a Series C, in Apr 2003.

Where is Xcel Pharmaceuticals based?

Xcel Pharmaceuticals is based in the United States.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.